|Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity|
J Tsai, JT Lee, W Wang, J Zhang, H Cho, S Mamo, R Bremer, S Gillette, ...
Proceedings of the National Academy of Sciences 105 (8), 3041-3046, 2008
|Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases|
KSM Smalley, NK Haass, PA Brafford, M Lioni, KT Flaherty, M Herlyn
Molecular cancer therapeutics 5 (5), 1136-1144, 2006
|Adhesion, migration and communication in melanocytes and melanoma|
NK Haass, KSM Smalley, L Li, M Herlyn
Pigment cell research 18 (3), 150-159, 2005
|An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells|
KSM Smalley, R Contractor, NK Haass, AN Kulp, GE Atilla-Gokcumen, ...
Cancer research 67 (1), 209-217, 2007
|The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when …|
NK Haass, K Sproesser, TK Nguyen, R Contractor, CA Medina, ...
Clinical Cancer Research 14 (1), 230-239, 2008
|Normal human melanocyte homeostasis as a paradigm for understanding melanoma|
NK Haass, M Herlyn
Journal of Investigative Dermatology Symposium Proceedings 10 (2), 153-163, 2005
|The role of altered cell–cell communication in melanoma progression|
NK Haass, KSM Smalley, M Herlyn
Journal of molecular histology 35 (3), 309-318, 2004
|PLX4032, a potent inhibitor of the B‐Raf V600E oncogene, selectively inhibits V600E‐positive melanomas|
JT Lee, L Li, PA Brafford, M Van Den Eijnden, MB Halloran, K Sproesser, ...
Pigment cell & melanoma research 23 (6), 820-827, 2010
|Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion|
KSM Smalley, P Brafford, NK Haass, JM Brandner, E Brown, M Herlyn
The American journal of pathology 166 (5), 1541-1554, 2005
|Targeting glutamine transport to suppress melanoma cell growth|
Q Wang, KA Beaumont, NJ Otte, J Font, CG Bailey, M van Geldermalsen, ...
International journal of cancer 135 (5), 1060-1071, 2014
|A novel class of anticancer compounds targets the actin cytoskeleton in tumor cells|
JR Stehn, NK Haass, T Bonello, M Desouza, G Kottyan, H Treutlein, ...
Cancer research 73 (16), 5169-5182, 2013
|Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737|
KM Lucas, N Mohana-Kumaran, D Lau, XD Zhang, P Hersey, DC Huang, ...
Clinical cancer research 18 (3), 783-795, 2012
|Detection of primary melanoma in individuals at extreme high risk: a prospective 5-year follow-up study|
FJ Moloney, P Guitera, E Coates, NK Haass, K Ho, R Khoury, ...
JAMA dermatology 150 (8), 819-827, 2014
|A stress-induced early innate response causes multidrug tolerance in melanoma|
DR Menon, S Das, C Krepler, A Vultur, B Rinner, S Schauer, K Kashofer, ...
Oncogene 34 (34), 4448-4459, 2015
|In vitro three-dimensional tumor microenvironment models for anticancer drug discovery|
KSM Smalley, M Lioni, K Noma, NK Haass, M Herlyn
Expert opinion on drug discovery 3 (1), 1-10, 2008
|Pantophysin is a ubiquitously expressed synaptophysin homologue and defines constitutive transport vesicles.|
NK Haass, MA Kartenbeck, RE Leube
The Journal of cell biology 134 (3), 731-746, 1996
|Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels|
KSM Smalley, R Contractor, NK Haass, JT Lee, KL Nathanson, ...
British journal of cancer 96 (3), 445-449, 2007
|Real‐time cell cycle imaging during melanoma growth, invasion, and drug response|
NK Haass, KA Beaumont, DS Hill, A Anfosso, P Mrass, MA Munoz, ...
Pigment cell & melanoma research 27 (5), 764-776, 2014
|Genetics of basal cell carcinoma|
SE De Zwaan, NK Haass
Australasian journal of dermatology 51 (2), 81-92, 2010
|Modeling melanoma in vitro and in vivo|
KA Beaumont, N Mohana-Kumaran, NK Haass
Healthcare 2 (1), 27-46, 2014